OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
10
Results
Show all
Save search
Copy query
Show results for
Unknown
(10)
Publication Date
Release Date
2025
(3)
2021
(3)
2024
(2)
2023
(2)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Discontinuation risk from adverse events: immunotherapy alone vs. combined with chemotherapy: a systematic review and network meta-analysis.
Not available
S-EPMC10825980
|
biostudies-literature
Cite
Korean Model for Post-acute Comprehensive rehabilitation (KOMPACT): The Study Protocol for a Pragmatic Multicenter Randomized Controlled Study on Early Supported Discharge.
Not available
S-EPMC8455937
|
biostudies-literature
Cite
Deep Learning Analysis of CT Images Reveals High-Grade Pathological Features to Predict Survival in Lung Adenocarcinoma.
Not available
S-EPMC8391458
|
biostudies-literature
Cite
Effect of sex-specific differences on function of induced hepatocyte-like cells generated from male and female mouse embryonic fibroblasts.
Not available
S-EPMC7831237
|
biostudies-literature
Cite
Deep learning model improves tumor-infiltrating lymphocyte evaluation and therapeutic response prediction in breast cancer.
Not available
S-EPMC10469174
|
biostudies-literature
Cite
Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18.
Not available
S-EPMC10485395
|
biostudies-literature
Cite
A universal immunohistochemistry analyzer for generalizing AI-driven assessment of immunohistochemistry across immunostains and cancer types.
Not available
S-EPMC11615360
|
biostudies-literature
Cite
Deep Learning Predicts EGFR Mutation Status from Histology Images in Non-Small Cell Lung Cancer.
Not available
S-EPMC12682618
|
biostudies-literature
Cite
Artificial Intelligence-Powered Spatial Analysis of Immune Phenotypes in Resected Pancreatic Cancer.
Not available
S-EPMC12199178
|
biostudies-literature
Cite
Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21).
Not available
S-EPMC12495080
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets